Scalepad Software Inc. – Trademark Portfolio

Entity Type: 03

Scalepad Software Inc. holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 36 (Insurance & Financial) — 3 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include SCALEPAD. The owner is based in Vancouver.

Suite 3200 - 1021 Hastings St. West

Vancouver V6E0C3 , CA

3 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Scalepad Software Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

36
Insurance & Financial (3 filings)

Insurance; financial affairs; monetary affairs; real estate affairs

42
Computer & Scientific (2 filings)

Scientific and technological services; industrial analysis and research services

Frequently Asked Questions

How many trademarks does Scalepad Software Inc. have?

Scalepad Software Inc. has 3 U.S. trademarks filed with the USPTO. Of these, 1 registered, 2 abandoned.

What trademark classes does Scalepad Software Inc. file in?

Scalepad Software Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 36 (Insurance & Financial), Class 42 (Computer & Scientific). Class 36 covers insurance; financial affairs; monetary affairs; real estate affairs.

What are Scalepad Software Inc.'s most well-known trademarks?

Scalepad Software Inc.'s registered trademark portfolio includes well-known marks such as SCALEPAD. These are among 1 currently registered trademark in the portfolio.

What is Scalepad Software Inc.'s trademark registration success rate?

Scalepad Software Inc. has a 33% trademark registration rate, with 1 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.